Scarica l'app Stockscreener
8.6806
4.49%
-0.4094
Precedente Chiudi:
$9.09
Aprire:
$8.99
Volume 24 ore:
464.22K
Relative Volume:
0.26
Capitalizzazione di mercato:
$755.31M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-4.0003
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+2.62%
1M Prestazione:
-19.54%
6M Prestazione:
+34.81%
1 anno Prestazione:
+5.74%
Intervallo 1D:
$8.61
$9.175
Intervallo di 1 settimana:
$8.13
$9.175
Portata 52W:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.68 | 790.99M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology (NASDAQ:KURA) Cut to "Strong Sell" at Zacks Research - MarketBeat
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology (NASDAQ:KURA) Nasdaq 100 Index Clinical Research Focus - Kalkine Media
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Does Kura Oncology (NASDAQ:KURA) Have A Healthy Balance Sheet? - 富途资讯
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 37.5% in December - MarketBeat
Kura Oncology's finance SVP sells shares worth $38,958 - MSN
Kura Oncology price target lowered to $20 from $25 at Leerink - Yahoo Finance
FY2025 EPS Forecast for Kura Oncology Reduced by Analyst - MarketBeat
Kura Oncology (KURA) Receives a Buy from Leerink Partners - The Globe and Mail
Inflation Data: Will Kura Oncology Inc stock keep outperforming rivalsJuly 2025 PreEarnings & Risk Controlled Swing Alerts - Bộ Nội Vụ
KURA: HC Wainwright & Co. Reiterates 'Buy' Rating and $40 PT | K - GuruFocus
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
Stock Recap: Whats the profit margin of Kura Oncology IncIPO Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA) - The Globe and Mail
Kura Oncology 8-K Filing Analysis - TradingView — Track All Markets
Kura Oncology Posts $2.1M Initial KOMZIFTI Sales, Secures $195M Milestone - Nasdaq
Kura Oncology Announces Launch of KOMZIFTI™ (ziftomenib) and Preliminary $2.1 Million Revenue Following FDA Approval for R/R NPM1-mutated AML - Quiver Quantitative
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - The Manila Times
Kura Oncology wins FDA approval for leukemia drug - MSN
Is Kura Oncology Inc. stock affected by interest rate hikesTrade Performance Summary & Fast Gain Stock Tips - Улправда
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors - Yahoo Finance
Can Kura Oncology Inc. stock sustain institutional interestJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
Rate Cut: Will Kura Oncology Inc. stock see insider buyingEarnings Summary Report & Consistent Return Strategy Ideas - Улправда
Aug Intraday: Is Kura Oncology Inc. stock affected by interest rate hikesWeekly Stock Analysis & Verified Swing Trading Watchlist - Улправда
FY2025 EPS Forecast for Kura Oncology Decreased by Analyst - MarketBeat
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" - Finviz
Kura Oncology (STU:KUR) EV-to-FCF : 3.00 (As of Dec. 23, 2025) - GuruFocus
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
7 Stocks That Were on Jim Cramer’s Radar - Insider Monkey
Kura Oncology (KURA) Shares Surge After FDA Approval and Cramer Endorsement - GuruFocus
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology (STU:KUR) EV-to-OCF : 2.87 (As of Dec. 22, 2025) - GuruFocus
Jim Cramer Discusses Kura Oncology as a Speculative Bet - Finviz
Kura Oncology (HAM:KUR) EV-to-OCF : 2.87 (As of Dec. 21, 2025) - GuruFocus
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):